News | Stents Bifurcation | October 28, 2016

Tryton Medical Partners With Cardinal Health for U.S. Distribution of Bifurcation Stent

Long-term collaboration for U.S. distribution of Tryton Side Branch Stent pending regulatory approval

tryton side branch stent, bifurcation stenting, Cardinal Health

October 28, 2016 – Tryton Medical Inc., a primary developer of stents to treat coronary bifurcation lesions, and Cardinal Health today announced that the companies have established a long-term strategic agreement for U.S. distribution of the Tryton Side Branch Stent, pending regulatory approval. Tryton submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Tryton Side Branch Stent in November 2015.
 
Bifurcation lesions are present in 20-30 percent of patients with coronary artery disease (CAD) who are treated with percutaneous coronary intervention (PCI). If approved, the Tryton Side Branch Stent would be the first stent specifically indicated for the treatment of bifurcation lesions in the United States.

 

Read the article "Tryton Completes Patient Enrollment in Pivotal FDA Side Branch Stent Trial."

 
“Bifurcation disease is one of the most significant unmet needs in interventional cardiology. The current practice of provisional stenting typically involves complex procedures with uncertain results,” said Shawn McCarthy, president and CEO of Tryton Medical. “Tryton is committed to providing physicians a predictable treatment strategy for bifurcation lesions based on an easy to use solution for any anatomical challenge. Pending our regulatory approval in the U.S., we are excited to collaborate with Cordis, Cardinal Health’s interventional vascular business, to achieve our goal of establishing a new standard of care with a definitive treatment for complex bifurcation disease.”
 
“In extensive clinical research, the Tryton Side Branch Stent has demonstrated an ability to provide predictability and durability when treating coronary bifurcation lesions with significant side branches,” said Dr. Martin Leon, director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, New York-Presbyterian Hospital. “This uniquely engineered stent has the potential to disrupt standard strategies for treating complex bifurcation lesions.”
 
During the 28th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Tryton will sponsor a clinical symposium entitled “Establishing the New Standard: Definitive Treatment for Complex Bifurcation Lesions.” The symposium featuring leading experts in the treatment of bifurcation will be held in Room 143B of the Walter E. Washington Convention Center in Washington, D.C. on Monday, Oct. 31 from 6:30-8 a.m. ET. Tryton is also exhibiting at booth 1343 at TCT 2016.
 
The Tryton Side Branch Stent System is built using proprietary Tri-Zone technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. Tryton Side Branch Stent has now been used to treat more than 11,000 patients worldwide. The Tryton Side Branch Stent is commercially available in multiple countries within Europe, Middle East and Africa, is investigational in the U.S., and is not available in Japan.
 

Read the article "New Stent Designs May Ease Bifurcation Stenting."

For more information: www.trytonmedical.com 

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th